EMEND

LOE Approaching

fosaprepitant dimeglumine

NDAINTRAVENOUSPOWDER
Approved
Jan 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
38

Mechanism of Action

accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…

Clinical Trials (5)

NCT04054193Phase 4Completed

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
NCT03578081Phase 3Completed

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Started Nov 2018
690 enrolled
Malignant Neoplasm
NCT02445872Phase 2Unknown

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Started Dec 2015
80 enrolled
Chemotherapy-Induced Nausea and VomitingLung Cancer
NCT01450826Phase 2Completed

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Started Jun 2014
136 enrolled
NauseaVomitingGlioma
NCT01736917Phase 2Completed

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Started Jan 2013
65 enrolled
Chemotherapy-Induced Nausea and Vomiting